FME:ETR
Fresenius Medical Care AG
€39.18
arrow_upward
+1.90%(+0.73) 1D
Oct 22, 5:35:23 PM GMT+2 · EUR
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for FME...
Open
€38.68
High
€39.28
Low
€38.37
Mkt. cap
10.46B
Avg. vol.
879.98K
Volume
0.00
Dividend
3.80%
Quarterly dividend
€0.37
Ex-dividend date
May 22, 2026
P/E ratio
11.78
52-wk high
€47.54
52-wk low
€34.57
EPS
€3.33
Shares outstanding
268.56M
No. of employees
107K
Open
€38.68
High
€39.28
Low
€38.37
Mkt. cap
10.46B
Avg. vol.
879.98K
Volume
0.00
Dividend
3.80%
Quarterly dividend
€0.37
Ex-dividend date
May 22, 2026
P/E ratio
11.78
52-wk high
€47.54
52-wk low
€34.57
EPS
€3.33
Shares outstanding
268.56M
No. of employees
107K
News stories
From web sources and news partners
Seeking Alpha
·
2 days ago
DaVita, Fresenius drop as HHS seeks dialysis market reforms (DVA:NYSE)
Profile
Fresenius Medical Care AG & Co. KGaA is a German healthcare company which provides kidney dialysis services through a network of 4,171 outpatient dialysis centers, serving 345,425 patients. The company primarily treats end-stage renal disease, which requires patients to undergo dialysis 3 times per week for the rest of their lives.
With a global headquarters in Bad Homburg vor der Höhe, Germany, and a North American headquarters in Waltham, Massachusetts, it has a 38% market share of the dialysis market in the United States. It also operates 42 production sites, the largest of which are in the U.S., Germany, and Japan.
The company is 32% owned by Fresenius and, as of 2020, generates around 50% of the group's revenue.
As of 2024, the company was ranked as #612 on the World's Best Employers list published by Forbes. Wikipedia
About Fresenius Medical Care AG
CEOHelen Giza
Employees107K
Founded1996
Headquarters-
SectorHealth care provider
Websitefreseniusmedicalcare.com
Next call in 12 days
Tue, Nov 3, 3:00 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (EUR)
- GAAP EPS / Est. (EUR)
- / €1.22
Revenue / Est. (EUR)
- / 4.92B
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in EUR | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 4.88B | 5.07B | 4.61B | 4.86B |
Cost of goods sold | 3.64B | 3.68B | 3.43B | 3.55B |
Cost of revenue | 3.64B | 3.68B | 3.43B | 3.55B |
Research and development expenses | 37.75M | 38.63M | 38.31M | 39.63M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 705.44M | 784.62M | 748.94M | 736.01M |
Operating expense | 740.50M | 796.34M | 803.94M | 786.35M |
Total operating expenses | 4.38B | 4.48B | 4.24B | 4.34B |
Operating income | 501.72M | 592.03M | 375.56M | 523.63M |
Other non operating income | - | - | - | - |
EBT including unusual items | 402.57M | 508.46M | 207.52M | 383.00M |
EBT excluding unusual items | 462.70M | 541.79M | 334.44M | 399.22M |
Income tax expense | 75.22M | 106.44M | 42.75M | 89.83M |
Effective tax rate | 18.69% | 20.93% | 20.60% | 23.45% |
Other operating expenses | -2.69M | -26.91M | 16.69M | 10.71M |
Net income | 274.80M | 327.08M | 117.53M | 218.38M |
Net profit margin | 5.63% | 6.45% | 2.55% | 4.49% |
Earnings per share | 1.10 | 1.44 | 0.91 | 0.56 |
Interest and investment income | 19.16M | 13.62M | 14.62M | 14.70M |
Interest expense | -93.10M | -99.02M | -93.30M | -97.55M |
Net interest expenses | -73.94M | -85.40M | -78.68M | -82.86M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 853.56M | 780.17M | 727.79M | 879.38M |
Gain or loss from assets sale | 50.35M | 17.92M | 8.77M | -4.09M |